Sharp contrasts among MERS-related stocks within a month after the occurrence of the first MERS patient
Since the 21st of the last month, when the first MERS-diagnosed patient occurred, both joy and sorrow has been exchanged among MERS-related stocks in a month.
The turning point of MERS-related stocks was the 2nd of this month; most MERS-benefited stocks hit their highest price.
Since the day, a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
